Zobrazeno 1 - 10
of 143
pro vyhledávání: '"ритуксимаб"'
Publikováno v:
Креативная хирургия и онкология, Vol 12, Iss 2, Pp 164-171 (2022)
The off-label use of medicines is a routine clinical practice of oncology, especially in malignant-tumour patients with no treatment alternatives left when registered-drug options have been exhausted or standard therapies reveal contraindications. Th
Externí odkaz:
https://doaj.org/article/c3e8a83e0fd6422b816023ec39d205af
Publikováno v:
Вестник Северо-Кавказского федерального университета, Vol 0, Iss 5, Pp 52-56 (2022)
The main aim of our research was to study the dynamics of indexes of lipid profile from patients with rheumatoid arthritis during 52 weeks. We have found that the therapy with rituximab in combination with me- totrexate brings the reduction of clinic
Externí odkaz:
https://doaj.org/article/4ac588f275c2420c8890083a6e677f3d
Autor:
L. P. Ananieva
Publikováno v:
Научно-практическая ревматология, Vol 58, Iss 5, Pp 520-531 (2020)
A significant progress has been made in recent years in management of severe systemic scleroderma (SSD) manifestations, such as Raynaud’s phenomenon, renal crisis, and pulmonary arterial hypertension, subsequently improving survival and quality of
Externí odkaz:
https://doaj.org/article/736bf8562a7b4fdaa68815500512b928
Publikováno v:
Креативная хирургия и онкология, Vol 9, Iss 2, Pp 125-131 (2019)
Introduction. Chronic lymphocytic leukaemia (CLL) is a malignant clonal lymphoproliferative disorder characterised by the accumulation of atypical mature CD5/CD19/CD23-positive B lymphocytes, predominantly in blood, bone marrow, lymph glands, liver a
Externí odkaz:
https://doaj.org/article/f935cfcfdf8b44fd9a387b95da415ce9
Autor:
Alla V Rudakova, Vladimir V Strugov
Publikováno v:
Современная онкология, Vol 21, Iss 2, Pp 29-32 (2019)
Background. Current treatment of relapsed/refractory chronic lymphocytic leukemia implies the use of regimens that include innovative drugs such as ibrutinib and a combination of venetoclax with rituximab. Herewith the combination of venetoclax with
Externí odkaz:
https://doaj.org/article/3d924aa74df24ca49dc3939e6a60aa58
Publikováno v:
Научно-практическая ревматология, Vol 0, Iss 0 (2018)
Резюме. Прогрессирующий системный склероз (системная склеродермия, ССД) – хроническое заболевание с плохим прогнозом, при котором на фо
Externí odkaz:
https://doaj.org/article/96ac5ac368d741e3979f43bf1e0f245e
Здравоохранение Чувашии, Выпуск 2 2023, Pages 63-75
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::54176725e192bbe2255609116335b157
Autor:
Tsanyan Maria E., Soloviev Sergey K., Radenska-Lopovok Stefka G., Torgashina Anna V., Nikolaeva Ekaterina V., Khrennikov Yaroslav B., Nasonov Evgeniy L.
Publikováno v:
Folia Medica, Vol 56, Iss 4, Pp 245-252 (2014)
Aim: TO assess the effects of rituximab (RTM) therapy on clinical and morphologic activity of lupus nephritis (LN).
Externí odkaz:
https://doaj.org/article/5bc641f78af54ae98d652dbb432d3a51
Autor:
Evgeni Lvovich Nasonov
Publikováno v:
Современная ревматология, Vol 3, Iss 4, Pp 67-75 (2009)
Rheumatoid arthritis (RA) is one of the most common and severe chronic inflammatory diseases. The paper reviews the recent studies evaluating the efficacy of rituximab (MabThera®), chimeric anti-CD20 monoclonal antibodies in B cells, in patients wit
Externí odkaz:
https://doaj.org/article/3bb08fc1e4fb45f08f52c1b71a35117d
Autor:
N B Mikhaylova
Publikováno v:
Современная онкология, Vol 11, Iss 3, Pp 28-31 (2009)
За последние 30 лет благодаря стремительному развитию молекулярной генетики и иммунологии радикальным образом изменилось представлени
Externí odkaz:
https://doaj.org/article/ee273da70a3e456fa1c397075e8582ba